C18 NC-TNP
DC60537
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | Si12-C10 |
| Synonyms | Si12 C10， Si12C10 |
| SMILES | CCCCCCCCC(O)CN(CCSCC[Si]1(C)O[Si](C)(CCSCCN(CC(O)CCCCCCCC)CC(O)CCCCCCCC)O[Si](C)(CCSCCS(=O)(=O)O)O1)CC(O)CCCCCCCC |
| Formula | C55H118O10N2S4Si3 |
| M.Wt | 1180.05 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery. DOI: 10.1038/s41565-024-01747-6 |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| Si12-C10 | 35 | Ionizable lipid |
| DOPE | 16 | Helper phospholipid |
| Cholesterol | 46.5 | Sterol |
| C14PEG2K (DMPE-PEG2000 as named in SI) | 2.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Formulation calculator unavailable. A calculation is not enabled where component molecular weights or a fixed molar recipe are unverified. C14PEG2K is named as a dimyristoyl phosphoethanolamine PEG lipid in SI p.5; it is not silently replaced with DMG-PEG. Screening Methods list ethanol/aqueous flow rates 1.8/0.6 mL/min; large-batch Methods explicitly use aqueous/ethanol 3:1. These methods are retained separately. N/P and buffer pH are not specified. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reportedSpleen-directed leadFLuc reporter screen; 0.25 mg/kg IV; expression is distinct from lipid accumulation · 6 hMain PDF p.6, Fig.3
Literature-reported5.84TNS assay; formulation-dependentMain PDF p.6; SI Fig.S28
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetCombinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery. DOI: 10.1038/s41565-024-01747-6 DOI: 10.1038/s41565-024-01747-6
C14PEG2K is named as a dimyristoyl phosphoethanolamine PEG lipid in SI p.5; it is not silently replaced with DMG-PEG. Screening Methods list ethanol/aqueous flow rates 1.8/0.6 mL/min; large-batch Methods explicitly use aqueous/ethanol 3:1. These methods are retained separately. N/P and buffer pH are not specified.
C14PEG2K is named as a dimyristoyl phosphoethanolamine PEG lipid in SI p.5; it is not silently replaced with DMG-PEG. Screening Methods list ethanol/aqueous flow rates 1.8/0.6 mL/min; large-batch Methods explicitly use aqueous/ethanol 3:1. These methods are retained separately. N/P and buffer pH are not specified.